Literature DB >> 19824698

Identification of the autophosphorylation sites of LRRK2.

Shogo Kamikawaji1, Genta Ito, Takeshi Iwatsubo.   

Abstract

Parkinson's disease (PD) is a major adult-onset neurodegenerative disorder affecting the extrapyramidal motor system. A subset of patients develop PD as an autosomal dominant trait, of which PARK8 caused by mutations in the leucine-rich repeat kinase 2 (LRRK2) gene is highlighted because of its high frequency and clinicopathological similarity to sporadic PD. Previous studies have suggested that overactivation of LRRK2 caused by missense mutations leads to neuronal toxicity in PARK8, although the regulatory mechanism that governs the kinase activity of LRRK2 remains unknown. In this study, we expressed the carboxyl-half fragments of LRRK2 (DeltaN-LRRK2) that harbors the kinase as well as the ras-like (ROC) domains in Sf9 cells, subjected them to in vitro phosphorylation reaction, and analyzed the autophosphorylation by matrix assisted laser desorption/ionization- time of flight (MALDI-TOF) mass spectrometer. We identified Ser1403, Thr1404, Thr1410, Thr1491 located within the ROC domain, as well as Thr1967 and Thr1969 in the kinase domain, as the autophosphorylation sites. Substitution of Thr1967, an autophosphorylation site located within the kinase domain, to Ala caused a significant decrease in the kinase activity, implicating Thr1967 in the kinase activity of LRRK2. Phosphospecific antibodies to the autophosphorylation sites specifically recognized full-length LRRK2 subjected to in vitro phosphorylation reaction, indicating that the autophosphorylation takes place in holoproteins. Further analysis of autophosphorylation will clarify the mechanism of activation of LRRK2, as well as the pathomechanism of PD in relation to overactivation of LRRK2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19824698     DOI: 10.1021/bi9011379

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  49 in total

Review 1.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

2.  Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.

Authors:  Veronique Daniëls; Renée Vancraenenbroeck; Bernard M H Law; Elisa Greggio; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Mark R Cookson; Kirsten Harvey; Veerle Baekelandt; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

3.  The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway.

Authors:  José M Bravo-San Pedro; Mireia Niso-Santano; Rubén Gómez-Sánchez; Elisa Pizarro-Estrella; Ana Aiastui-Pujana; Ana Gorostidi; Vicente Climent; Rakel López de Maturana; Rosario Sanchez-Pernaute; Adolfo López de Munain; José M Fuentes; Rosa A González-Polo
Journal:  Cell Mol Life Sci       Date:  2012-07-08       Impact factor: 9.261

4.  Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.

Authors:  Miguel Mendivil-Perez; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio
Journal:  Neurochem Res       Date:  2016-07-09       Impact factor: 3.996

Review 5.  Role of LRRK2 kinase dysfunction in Parkinson disease.

Authors:  Azad Kumar; Mark R Cookson
Journal:  Expert Rev Mol Med       Date:  2011-06-13       Impact factor: 5.600

Review 6.  Mechanisms of LRRK2-mediated neurodegeneration.

Authors:  Elpida Tsika; Darren J Moore
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

7.  Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities.

Authors:  Philip J Webber; Archer D Smith; Saurabh Sen; Matthew B Renfrow; James A Mobley; Andrew B West
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

Review 8.  Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Authors:  Iakov N Rudenko; Mark R Cookson
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

9.  ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2.

Authors:  Karina Haebig; Christian Johannes Gloeckner; Marta Garcia Miralles; Frank Gillardon; Claudia Schulte; Olaf Riess; Marius Ueffing; Saskia Biskup; Michael Bonin
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

10.  The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation.

Authors:  Azad Kumar; Elisa Greggio; Alexandra Beilina; Alice Kaganovich; Diane Chan; Jean-Marc Taymans; Benjamin Wolozin; Mark R Cookson
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.